1. OP0002 Tofacitinib in Patients with Ankylosing Spondylitis: A Phase 2, 16-Week, Randomised, Placebo-Controlled, Dose-Ranging Study. (15th July 2016) Authors: van der Heijde, D.; Deodhar, A.; Wei, J.C.; Drescher, E.; Fleishaker, D.; Hendrikx, T.; Li, D.; Menon, S.; Kanik, K. Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 2 Page Start: 52 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. OP0225 TOFACITINIB AS MONOTHERAPY FOLLOWING METHOTREXATE WITHDRAWAL IN PATIENTS WITH PSORIATIC ARTHRITIS PREVIOUSLY TREATED WITH OPEN-LABEL TOFACITINIB + METHOTREXATE: A RANDOMISED, PLACEBO-CONTROLLED SUBSTUDY OF OPAL BALANCE. (2nd June 2020) Authors: Nash, P.; Coates, L. C.; Mease, P. J.; Kivitz, A.; Gladman, D. D.; Behrens, F.; Wei, J. C. C.; Fleishaker, D.; Wu, J.; Wang, C.; Romero, A. B.; Fallon, L.; Hsu, M. A.; Kanik, K. Journal: Annals of the rheumatic diseases Issue: Volume 79(2020)Supplement 1 Page Start: 140 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. SAT0293 Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of opal balance, an open-label, long-term extension study. (12th June 2018) Authors: Nash, P.; Coates, L.C.; Kivitz, A.J.; Mease, P.J.; Gladman, D.D.; Covarrubias-Cobos, J.A.; Fleishaker, D.; Wang, C.; Kudlacz, E.; Menon, S.; Fallon, L.; Hendrikx, T.; Kanik, K.S. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 1010 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗